Azilect(rasagiline)
Azilect, Rasagiline (rasagiline) is a small molecule pharmaceutical. Rasagiline was first approved as Azilect on 2005-02-21. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against amine oxidase [flavin-containing] B.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
Azilect, Rasagiline (discontinued: Rasagiline)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| azilect | New Drug Application | 2021-04-02 |
| rasagiline | ANDA | 2024-09-18 |
| rasagiline mesylate | ANDA | 2023-10-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| parkinson disease | EFO_0002508 | D010300 | G20 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
63 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Parkinson disease | D010300 | EFO_0002508 | G20 | 5 | 3 | 17 | 17 | 9 | 49 |
| Cognitive dysfunction | D060825 | HP_0001268 | G31.84 | — | — | — | 2 | — | 2 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | — | — | 1 | — | 1 |
| Dissociative disorders | D004213 | — | F44.1 | — | — | — | 1 | — | 1 |
| Apathy | D057565 | HP_0000741 | — | — | — | — | 1 | — | 1 |
| Sleep wake disorders | D012893 | — | G47 | — | — | — | 1 | — | 1 |
| Dyssomnias | D020920 | — | — | — | — | — | 1 | — | 1 |
| Parasomnias | D020447 | — | G47.5 | — | — | — | 1 | — | 1 |
| Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | 1 | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | — | 1 | — | 1 |
Show 2 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Progressive supranuclear palsy | D013494 | EFO_0002512 | G23.1 | — | — | 1 | — | — | 1 |
| Paralysis | D010243 | HP_0003470 | — | — | — | 1 | — | — | 1 |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | — | 1 | 1 | — | — | 1 |
| Psychomotor agitation | D011595 | — | — | — | 1 | 1 | — | — | 1 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 1 |
| Rem sleep behavior disorder | D020187 | EFO_0007462 | G47.52 | — | 1 | 1 | — | — | 1 |
| Synucleinopathies | D000080874 | — | — | — | 1 | 1 | — | — | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Amyotrophic lateral sclerosis | D000690 | HP_0007354 | G12.21 | — | 3 | — | — | — | 3 |
| Motor neuron disease | D016472 | EFO_0003782 | G12.2 | — | 3 | — | — | — | 3 |
| Sclerosis | D012598 | — | — | — | 3 | — | — | — | 3 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 2 | — | — | — | 2 |
| Brain injuries | D001930 | — | S06.9 | 1 | 1 | — | — | — | 1 |
| Consciousness disorders | D003244 | — | — | 1 | 1 | — | — | — | 1 |
| Disease progression | D018450 | — | — | — | 1 | — | — | — | 1 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | 1 | — | — | — | 1 |
| Multiple system atrophy | D019578 | — | — | — | 1 | — | — | — | 1 |
| Atrophy | D001284 | — | — | — | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malignant carcinoid syndrome | D008303 | — | E34.0 | — | — | — | — | 1 | 1 |
| Serotonin syndrome | D020230 | EFO_1001842 | — | — | — | — | — | 1 | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | — | — | 1 | 1 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | — | — | — | 1 | 1 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Rasagiline |
| INN | rasagiline |
| Description | Rasagiline is an indane that consists of 1-aminoindane bearing an N-propargyl substituent. A selective, irreversible monoamine oxidase-B inhibitor. It has a role as an EC 1.4.3.4 (monoamine oxidase) inhibitor and a neuroprotective agent. It is a secondary amine, a member of indanes and a terminal acetylenic compound. |
| Classification | Small molecule |
| Drug class | Monoamine oxidase (MAO) inhibitors, type B |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#CCN[C@@H]1CCc2ccccc21 |
Identifiers
| PDB | — |
| CAS-ID | 136236-51-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL887 |
| ChEBI ID | 63620 |
| PubChem CID | 3052776 |
| DrugBank | DB01367 |
| UNII ID | 003N66TS6T (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,235 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,960 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use